Castle Biosciences (CSTL)
(Delayed Data from NSDQ)
$30.36 USD
-0.89 (-2.85%)
Updated Sep 18, 2024 04:00 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
CSTL 30.36 -0.89(-2.85%)
Will CSTL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CSTL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CSTL
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
CSTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Castle Biosciences, Inc. (CSTL) Report Negative Earnings Next Week? What You Should Know
Zacks Market Edge Highlights: Soundhound AI, Afya, Castle Biosciences, TriMas and Immersion
5 Top Small Cap Stocks to Buy Now
Other News for CSTL
Castle Biosciences? Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
DecisionDx?-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
Castle Biosciences: DecisionDx -Melanoma can precise predict SLN positivity risk
Study Confirms the Ability of Castle Biosciences' DecisionDx?-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
Castle Biosciences: New study shows DecisionDx-SCC test benefits SCC patients